

Office of the Nelson Mandela Bay Health District Manager
Private Bag X28000 • Greenacres • PORT ELIZABETH • 6057 • REPUBLIC OF SOUTH AFRICA

MEMORANDUM

	The CEO of:
То:	Empilweni TB Hospital
	Jose Pearson TB Hospital
	Orsmond TB Hospital
	The Manager : Pharmaceutical Depot
	The Deputy Director : TB, NMBHD, Mrs. B. Ncanywa
	The Deputy Director: Clinical Support Services, NMBHD, Mrs. M. Manuel
	District Pharmacist, NMBHD, Ms. T. Lategan
	Senior Clinical Manager NMBHD, Dr. F. Fourie
rom:	Dr. L.P. Mayekiso - District Ma
Date:	27 January 2014 Contact Number: 041-391-8008

DIRECTIVE INSTRUCTING THE DISPENSING OF IMMUTIDES TO ALL PATIENTS IN TB HOSPITALS IN THE NMBHD

BACKGROUND

Immutides Spray is a non-scheduled, natural product, produced from bovine colostrum. It contains Proline-Rich Polypeptides that accelerate the maturation of CD 4 Lymphocytes in the Thymus and thereby increasing the patients CD 4 count. This in turn leads to a stronger immune system.

This directive serves to instruct the launch of three projects:

Project 1:

Immutides spray must be dispensed to all patients in the 3 TB hospitals of the NMBHD and any new patients admitted there-after, starting from **01 March 2014**.

All these patients must stay on Immutides Spray for the duration of their TB treatment. On discharge from the hospital they must be issued with a script for Immutides Spray from the doctor at the hospital. The clinics will then provide the Immutides Spray for the remainder of their TB treatment.

The goal is to boost the immune system of patients, so badly affected by TB that they needed admission to

United in achieving quality health care for all

24 hour call centre: 0800 0323 64 Website: www.ecdoh.gov.za



The hospitals and Pharmaceutical depot must please prepare for this project and order the Immutides Spray so that their pharmacies are ready for roll out on 01/03/2013.

Project 2:

A research project must be launched that will evaluate the effect of adding Immutides Spray to the treatment regime of all TB patients admitted to a TB hospital.

This research project must run for **6 months**, starting from 01/03/2014 up to 31/08/2014. The final written report must be ready for presentation on 31/10/2014.

Project3:

During November 2014, the research report will be evaluated by the Top Management of the NMBHD and the future use of Immutides Spray will be evaluated.

Please note:

The initiation of Immutides Spray at the TB hospitals will continue during the compiling and evaluation of the research report.

CONCLUSION

It is with great excitement that I give this directive in an effort to investigate every means to our disposal to facilitate better outcomes for our TB patients.

I would like to thank all stake holders who will be involved in this project in advance and may God bless our effort.

DR. L.P. MAYEKISO
DISTRICT MANAGER

DISTRICT MANAGER HEALTH PRIVATE BAG X28000 6057 GREENACRES, P.E.







DEPARTMENT OF HEALTH Rapublic of South Africa

TO:

IMMUTRITION Pty (Ltd)

FOR

ATTENTION:

G. SAULEZ / M. XEGO

FAX NO:

041-374 2041

1

NO OF PAGES:

(Including this

one)

DATE 13/09/2011

SUBJECT: SUBMISSION OF INFORMATION IN TERMS OF GOVERNMENT GAZETTE NOTICE

MESSAGE: Your request dated 12/09/2011 has reference:

The following products submitted as complimentary medicines in terms of Government Gazette Notice 23128; read with Section 14(1) of the Medicines and Related Substances Act; Act 101 of 1965 may be imported and sold as Complimentary Medicine in South Africa.

1. IMMUTIDES SPRAY

Should you require any additional information, please do not hesitate to contact this office.

Regards

PHARMACEUTICAL AND RELATED PRODUCT REGULATION MANAGEMENT. DEPARTMENT

INSPECTORATE & LAW ENFORCEMENT

PE BEKKER

FAX NO:

0866096628

Tel: 0824416003

THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND CONTAINS INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS DOCUMENTATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY

Room 152 • 1st Floor • Dukumbana Building • Independence Avenue • Bhisho • Eastern Cape Private Bag X0038 • Bhisho • 5605 • REPUBLIC OF SOUTH AFRICA

Tel.: +27 (0)40 608 1223 • Fax: +27 (0)86 560 9632 • Website: www.ecdoh.gov.za nomalanga.makwedini@impilo.ecprov.gov.za; biziwe.xongwana@impilo.ecprov.gov.za

March 20, 2012

G Saulez/M Xego

Saulez Agencies cc

10 Mortimer Road

Mill Park

PORT ELIZABETH

RE: ACKNOWLEDGEMENT OF APPROVAL - IMMUTIDES SPRAY

The Eastern Cape Department of Health hereby confirms that Saulez Agencies co applied to the National Department of Health for approval to register and supply Immutides Spray as complimentary medicine.

According to the documents which were received from the National Department of Health, which are attached to this communiqué, permission has been granted for Immutides Spray to be imported and sold as complimentary medicine, in accordance with the provisions of Government Gazette Notice 23128.

MRS NP MAKWEDINI

ACTING DDG: CLINICAL MANAGEMENT SERVICES

DATE